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Purpose
Collecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor
prognosis, accountings for less than 1% of all renal cancers. To date, no standard
therapy for CDC has been established. The aim of this study is an investigation of
clinicopathologic findings of CDC and correlation of the disease status with a prog-
nosis.
Materials and Methods
From 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The
diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in
eight cases.
Results
Median PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4
months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was
69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6
months (95% CI 0 to 23.3), which showed a statistically significant difference
(p=0.01). In addition, among patients with Stage IV, the OS of patients who received
a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4
months, which was higher than the OS of patients without treatment of 4.5 months. 
Conclusion
CDC is a highly aggressive form of renal cell carcinoma. Despite most of the treat-
ments, PFS and OS were short, however, there were some long-term survivors, there-
fore, conduct of additional research on the predictive markers of the several clinical,
pathological differences and their treatments will be necessary.
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Introduction
Collecting duct carcinoma (CDC) of the kidney is an 
unusual variant of renal cell carcinoma (RCC), accountings
for less than 1% of all renal cancers [1]. CDC arises precisely
from the principal cells lining distal collecting ducts of 
epithelium and distal renal tubules that originates from
mesonephros [2,3]. Considering that urothelial carcinoma
originating from the ureter, pelvis, or calices also arises from
the mesonephros, CDC might be similar to urothelial carci-
noma and its radiologic and pathologic findings differ from
those of other RCCs. Recent publications have pointed out
the histological heterogeneity of this neoplasm and its exten-
sive histological overlapping with high grade papillary 
tumors and urothelial carcinoma [4]. Accurate diagnosis is
important for proper management. In diagnosis of CDC, it
is important to distinguish between invasive papillary RCC
and urothelial carcinoma. Positive immunohistochemical
staining for distal tubules and collecting duct markers is
helpful indiscrimination of CDC from the more commonly
diagnosed clear cell RCC of proximal nephron origin [5].
CDC generally expresses broad spectrum keratins and high
molecular weight (HMW) cytokeratin, which is expressed in
the lower nephron and the urothelium. It also shows positive
staining with E-cadherin, epithelial membrane antigen,
CKβE12, and CK19. However, CD10, c-KIT, and a-methyla-
cylCoA racemase (AMACR) show no staining. In contrast,
papillary RCC showed positive results for CD10 and
AMACR, and it appears to be different from CDC [6]. 
However, this immunohistochemistry is not specific and
may be seen in medullary carcinomas and in urothelial 
carcinoma, including those arising in the renal pelvis [7].
Charaterization of CDC is difficult due to its low incidence.
Although the gross and microscopic features of the tumor
are well established, diagnostic confusion can still occur.
The most common presenting symptoms include gross
hematuria, pain, and general weakness. CDC is also found
with a palpable abdominal mass on physical examination.
CDC presents clinical features similar to those of other RCCs.
However, lymph node metastasis and distant metastasis
occur more frequently in CDC. CDC is an aggressive disease
with a poor prognosis. At diagnosis, 40% of patients have 
already developed metastatic lesions, including lymphnodes,
lungs, or adrenal glands [2,8]. Clinical outcome is poor, with
66% of patients dying of the disease within two years after
diagnosis [9]. Various treatments have been proposed, 
including radiation therapy, immunotherapy, and some
combinations of chemotherapy, however, results have been
unsatisfactory. 
To date, no standard therapy for CDC has been estab-
lished. The aim of this study is to conduct an investigation
of the clinicopathologic findings of CDC and to determine
their correlation with the disease status and prognosis. 
Materials and Methods 
We retrospectively reviewed 35 patients diagnosed with
CDC at eight Korean medical centers from 1996 to 2009. Data
on gender, age, initial symptoms, and laboratory findings,
including complete blood count profile, calcium, and urine
analysis, pathological features, treatment, and patient 
outcome were obtained from patient medical records. Diag-
nosis of CDC was made by examination of a nephrectomy
specimen in 27 cases and by renal biopsy in eight. Patholog-
ical studies included light microscopy and immunohisto-
chemistry. Tumors were staged according to the 2002
American Joint Committee on Cancer (AJCC) TNM stage
classification. Patient outcome was assessed by computed 
tomography. This study was approved by the Institutional
Review Board (IRB) from each participating institution. 
Tumor response after treatment was re-evaluated using
the Response Evaluation Criteria in Solid Tumors (RECIST
ver. 1.0) [10]. Progression free survival (PFS) was estimated
from the date treatment began to the date when disease 
progression was recognized, or the date of the last follow-up
visit, or the date of death. Overall survival (OS) was esti-
mated from the date of diagnosis to the date of death from
Table 1. Patients’ characteristics
Characteristic No. (%) (n=35)
Median age 56 (29-82)
Gender (%)
Male 25 (74)
Female 10 (26)
ECOG performance status
0-1 31 (88)
2 4 (12)
Initial symptoms (%)
Asymptomatic 3 (9)
Symptomatic 32 (91)
Pain 16 (44)
Hematuria 14 (39)
Weight loss 5 (14)
Palpable mass 1 (3)
Median hemoglobin (g/dL) 12.5 (8.9-18.3)
Median calcium (g/dL) 9.3 (7.9-11.1)
Values are presented as number (range or %). ECOG, 
Eastern Cooperative Oncology Group.
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any cause or the last follow-up visit.
OS and PFS were estimated using the Kaplan-Meier prod-
uct-limit method. Survival rates were compared for statistical
differences using log-rank analysis. The Cox regression
model was used for multivariate analysis with factors that
had been used in univariate (log rank) analysis of OS and
PFS. All statistical analyses were performed using the SPSS
ver. 14.0 (SPSS Inc., Chicago, IL) for Windows. p-values less
than 0.05 were considered statistically significant and all 
p-values correspond to two-sided significance tests.
Results
A list of patient and tumor characteristics is shown in 
Tables 1 and 2. The median age of patients was 56 years
(range, 29 to 82 years) and 74% of the patients were male. Of
32 symptomatic patients, 16 and 11 experienced pain and
gross hematuria. Other presenting symptoms included
weight loss, microscopic hematuria, and a palpable mass.
Seventeen patients had a tumor size of 7 cm or less, and 10
patients had a tumor size of 7 cm or greater. The median level
of hemoglobin and calcium was 12.5 g/dL (range, 8.9 to 18.3
g/dL) and 9.30 g/dL (range, 7.9 to 11.1 g/dL), respectively.
According to the immunohistochemistry finding, CDC 
expressed cytokeratin in nine patients (26%), HMW-cytoker-
atin in 14 (40%), low molecular weight-cytokeratin in three
(8.6%), and CKβE12F in one (2.9%). It also expressed CD10
in five (14.3%) and vimentin in 11 (31.4%). At diagnosis, nine,
two, four, and 19 patients had TNM stage I, II, III, and IV, 
respectively. Eight patients had two or more metastatic sites
of the bone (44%), lungs (39%), liver (16%), and lymph nodes
(11%) as the most common sites. 
With a median follow-up period of 15.8 months (range, 0.6
to 88.4 months), 14 (40%) deaths were reported. During the
median follow-up period of 15.8 months, 14 patients died,
while nine patients (25.7%) were lost in the follow-up.
Twenty seven of the 35 patients underwent nephrectomy for
initial treatment (curative surgery in 17, and palliative in 10),
three patients received chemotherapy, and four patients did
not receive any treatment (Fig. 1). Palliative chemotherapy
was administered for 22 persons, who were composed of
eight of 14 relapsed patients, eight of 10 patients who were
in stage IV and underwent palliative surgery, and four 
patients who did not undergo an operation (Fig. 1). The types
of palliative treatment administered to patients are shown in
Fig. 1. Median PFS and OS for all patients were 5.8 months
(95% confidence interval [CI], 3.5 to 9.2 months) and 54.4
months (95% CI, 0 to 109.2 months), respectively (Figs. 2 and
3A). The OS of the patients with stages I-III was 69.9 months
(95% CI, 54.0 to 85.8 months), while that of patients with
stage IV was 8.6 months, which showed a statistical signifi-
cant difference (p=0.01) (Fig. 3B). In addition, among 
patients with stage IV, the OS of patients who received a 
palliative treatment (immunotherapy, chemotherapy, or 
targeted therapy) was 18.4 months, which was higher than
the OS of patients without treatment of 4.5 months. The PFS
of patients with stages I-III was 6.9 months (95% CI, 1.3 to
12.4 months). Recurrence occurred in 14 patients, 82% of the
17 patients who underwent a curative surgery, and their 
average recurrence period was 5.9 months, with a short PFS
and a high relapse rate.
Using the log-rank method, no relationship was demon-
strated between survival end points (PFS and OS) and 
explanatory covariates, including patients’ age, gender, and
initial calcium level, except for hemoglobin (p=0.005 and
p=0.193, respectively) and initial TNM stage (p=0.022 and
p=0.002, respectively). Results of multivariate regression
analysis using a Cox’s proportional hazards model showed
that TNM stage (I-III vs. IV; hazard ratio, 4.58; 95% CI, 1.301
to 16.135; p=0.018) was an independent prognostic factor for
survival of CDC (Table 3).
Table 2. Tumor characteristics
Characteristic No. (%) (n=35)
Tumor size (cm)
＜7 17 (49)
≥7 10 (29)
Unknown 8 (22)
Lymph node status by imaging or surgery
N0 0 (0)
N1 18 (51)
N2 12 (34)
Unknown 5 (15)
TNM stage (AJCC 6th)
Stage I 9 (26)
Stage II 2 (6)
Stage III 4 (11)
Stage IV 19 (54)
Unknown 1 (3)
No. of metastasis sites
1 8 (23)
2 or greater 8 (20)
Metastasis site (%)
Bone 9 (26)
Lung 8 (23)
Lymph nodes 3 (9)
Liver 2 (6)
Others 1 (3)
AJCC, American Joint Committee on Cancer.
Kyung A Kwon, Collecting Duct Carcinoma of Kidney
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Table 3. Multivariate analysis for overall survival
Statement p-value Hazard ratio 95% Confidence interval
T 0.45 0.68 0.25-1.84 
N 0.45 0.84 0.19-3.73
Size (＜7 cm vs. ≥7 cm) 0.92 1.13 0.09-13.73 
Stage (I-III vs. IV) 0.03 49.58 1.55-1,584.01
Age (＜50 yr vs. ≥50 yr) 0.74 1.34 0.24-7.44
Hb (12 g/dL vs. ≥12 g/dL) 0.43 1.20 0.38-10.50 
Ca (10 mg/dL vs. ≥10 mg/dL) 0.46 1.77 0.40-7.90
Stage Ⅰ-Ⅲ
n=15
Stage Ⅳ
n=19
Stage unknown
n=1
Palliative surgery
n=10
No surgery
n=7
Curative surgery
n=17
No adjuvant
treatment
n=14
Pallliative
radiation 
therapy
n=2
Pallliative
immunotherapy/
Chemotherapy/
Targeted therapy 
n=22
Immunotherapy
   IFN
   IFN/5-FU
   IFN/IL-2
   IFN/IL-2/5-FU
Chemotherapy
   GMAC
   MVAC
   GP
   GC
   Unknown
Targeted therapy
   Temsirolimus
   Sunitinib
n=10
n=6
n=2
n=1
n=1
n=8
n=1
n=1
n=3
n=2
n=1
n=4
n=1
n=3
No treatment
n=4
No treatment
n=4
Adjuvant
chemotherapy   n=3
MVAC   n=1
IFN        n=2 
NED
n=3
Relapse
n=14
Fig. 1. Summary of treatment results. MVAC, methotrexate, vinblastin, Adriamycin, and cisplatin; IFN, interferon; NED, 
no evidence of disease; 5-FU, 5-fluorouracil; IL-2, interleukin-2; GMAC, gemcitabine, methotrexate, Adriamycin, and 
cisplatin; GP, gemcitabine and cisplatin; GC, gemcitabine and carboplatin.
n=10 n=7n=2
n=2 n=7 n=4 n=3n=3n=14
n=11
n=10
n=3
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Discussion
CDC of the kidney is known to be a rare and unique 
disease. The frequency of CDC is within 1% of the entire RCC
and its radiologic and pathologic findings differ from those
of other RCCs. In 1976, Mancilla-Jimenez et al. [11] reported
on 34 cases of papillary RCC and postulated a collecting duct
origin for three of these tumors based on the findings of 
atypical hyperplastic changes in adjacent collecting tubules.
In Korea, several CDCs have been reported in the literature
[12-14]. This is the first report on CDC based on medical
records from eight institutions in Korea. In Japan, a retro-
spective survey was conducted in order to analyze the nature
of CDC [15]. In the study, the central pathologists confirmed
CDC in 81 of 120 cases diagnosed as CDC at 66 institutions.
It was a large-scale nationwide survey with an advantage of
a multi-institutional central review. However, there were no
outcome reports on the responses for each treatment. On the
other hand, in this study, 35 patients were selected from eight
different organizations nationwide in Korea. Although 
a pathological central review was not performed, there was
significant detailed information on each case with the pattern
of cases and treatment outcomes. Thus, based on such infor-
mation, the results were evaluated with regard to the types
of post operational treatment and the drugs used as palliative
treatment and the responses.
Our results are in agreement with those of previous reports
showing that the median age was 56 years (range, 29 to 82
years) and that males comprised 74% of the patient popula-
tion. In our study, CDC expressed cytokeratin, HMW-cytok-
eratin, and CKβE12 in many cases, however, it also expressed
CD10 and vimentin, which is generally expressed in the
upper nephron, and not in the lower nephron. Ninety-one
percent of patients had symptoms and the most common
presenting symptoms were pain, hematuria, and weight loss.
At diagnosis, 19 (54%) patients were TNM stage IV, and the
median OS period of patients with stage IV was 9.29 months
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Fig. 2. Progression free survival (PFS) for all patients. CI,
confidence interval.
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Fig. 3. Overall survival (OS). (A) OS for all patients. (B) OS for patients with stage I-III (red) and IV (green). OS, overall
survival; CI, confidence interval.
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(95% CI, 0.0 to 26.78 months).
A summary of the clinical data on CDC gathered from
published series and case reports is shown in Table 4. Due
to the rarity of its occurrence, optimal treatment for CDC has
not been established. Despite past reports on striking 
responses to cytokines, currently, immunotherapy only has
an historical role. CDC might be distinct from conventional
RCC and share embryological origins and biological features
with urothelial carcinoma. Therefore, even if trials compar-
ing immunotherapy with chemotherapy have not been 
conducted, chemotherapy currently represents the most used
therapeutic approach. However, it remains unclear whether
this carcinoma should be managed with a treatment similar
to that for urothelial cell carcinoma or RCC. Multiple
chemotherapeutic and/or immunotherapeutic regimens
have been tried for treatment of CDC (Table 4). These data
appear to suggest that chemotherapy and immunotherapy
may offer only limited benefits to a selected group of 
patients. 
In our study, surgical treatment was performed as the 
initial treatment in 77% of patients. However, recurrence 
occurred in most patients who underwent surgery and a 
palliative treatment was administered in 75% of patients.
Most patients with advanced or recurrent disease were
treated with immunotherapy, chemotherapy, radiation ther-
apy, or targeted therapy. The most commonly used agents
included interferon, gemcitabine, cisplatin/carboplatin, and
sunitinib. The total OS was 54 months, while the PFS was
only 5.8 months. It seems that patients with stages I-III had
a high relapse rate with a short PFS of 6.9 months, while
seven patients (58%) with stages I-III survived for a long time
with patients in the no evidence of disease state, contributing
to the increase of the OS, so that there was a discrepancy 
between the PFS and the OS. Most of the long-term survivors
were in stages I-III and those who received palliative treat-
ment after a relapse, and the treatments administered to
these patients included target therapy as well as immuno-
therapy and chemotherapy. Due to the small number of 
patients, the correlation between the prognosis and the treat-
ment could not be known. However, it can be assumed that
palliative treatment takes the role of extending survival. 
In paticular, the current standard therapy against RCC is the
targeted therapy, and though it is recognized as a different
disease from RCC, there were some CDC patients who were
treated with sunitinib, temsirolimus, or other targeted
agents, different from the past. 
According to an analysis of clinical aspects, treatment and
prognosis in the records of seven CDC patients diagnosed
Table 4. Summary of previous reports for treatment modalities and therapeutic regimens
References Initial treatment Major therapeutic regimens Survival
Dimopoulos et al. [8] Surgery MVAC 1 NED (30 mo) 
Chemotherapy 5-FU/IFN-α/MMC 1 minor response (5 mo)
Immunotherapy IL-2/IFN-α 3 SD (10, 15, and 16 mo)
Median survival 22 mo
Chao et al. [16] Surgery Paclitaxel/carboplatin 2 NED (＜1 mo, 5 yr)
4 died (7-17, average 11.5 mo)
Peyromaure et al. [17] Surgery IFN-α 4 NED (9, 13, 17, and 27 mo)
Prednisolone 2 died (5, 24 mo)
Gemcitabine/cisplatin 3 loss
Mejean et al. [18] Surgery IFN-α 2 NED (99, 100 mo)
8 died (3 postop, 6-21 mo)
Tokuda et al. [15] Surgery Immunotherapy 1, 3, 5, and 10-yr survival
Chemotherapy 69.0%, 45.3%, 34.3%, and 13.7%
Oudard et al. [9] Surgery Gemcitabine/platinum Median OS 10.5 mo
Chemotherapy
Present study Surgery Immunotherapy 4 NED (81.7-88.8, median 88.2 mo)
(curative 17, palliative 10) Gemcitabine/platinum 8 alive with disease 
Chemotherapy MVAC, GMAC (19.1-82.6, median 26.9 mo)
Sunitinib, temsirolimus 14 died (0.63-54.37, median 7.8 mo)
9 loss
MVAC, methotrexate, vinblastin, Adriamycin, and cisplatin; NED, no evidence of disease; 5-FU, 5-fluorouracil; IFN, interferon;
MMC, mitomycin C; IL-2, interleukin-2; SD, stable disease; OS, overall survival; MVAC, methotrexate, vinblastin, Adriamycin,
and cisplatin; GMAC, gemcitabine, methotrexate, Adriamycin, and cisplatin.
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with RCC in Procopio’s study and included in patients
treated with the target therapy, five persons showed survival
of four months while two patients showed long-term 
survival of 49 months and 19 months, respectively [19]. 
In this study of the patients who were recently diagnosed
and received a target therapy, one patient for whom suni-
tinib was used finally died, but showed a partial response 
during treatment. 
CDC is an aggressive disease with poor prognosis, 
however, like some patients in this study who survived for
a long period of time, a study on predictive markers by
which the outcomes of prognosis and therapy, especially 
target therapy as well as their clinical features can be 
predicted is needed.
Conclusion
CDC is a highly aggressive form of RCC. Despite most of
the treatments, PFS and OS were short, however, there were
some long-term survivors, therefore, additional research on
the predictive markers of several clinical, pathological differ-
ences and their treatments will be needed.
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